Authors


Carlos Rojas, MD

Latest:

About the Continued Evaluation of MK-1084 for NSCLC and More

Carlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.


Mikkael Sekeres, MD

Latest:

Azacitadine Plus Pevonedistat Shows Efficacy in MDS/CMML or LB AML

Mikkael Sekeres, MD, discusses a phase 2 study of pevonedistat plus azacitidine versus azacitadine monotherapy in patients with higher-risk myelodysplastic syndromes /chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia.


Jerald P. Radich, MD

Latest:

Evaluating Ways of Measuring MRD in Hematologic Malignancies

Jerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.


Nicholas J. Robert, MD

Latest:

Racial Disparity Seen in Use of Germline Testing in TNBC

Nicholas J. Robert, MD, discusses a study of the social determinants of a patient’s health related to the use of genomic testing in women with breast cancer.


Hedyeh Ebrahimi, MD, MPH

Latest:

The Gut Microbiome and Immunotherapy: New Research Explores CBM588's Mechanism in mRCC

Hedyeh Ebrahimi, MD, MPH, discusses a study that found adding the live bacterial product CBM588 to standard immunotherapy potentially impacted patients' responses in renal cell carcinoma.


Ryan Scott

Latest:

Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC

In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.


Senthil Damodaran, MD, PhD

Latest:

Futibatinib Shows Promise in Breast Cancer With FGFR1 Gene Amplifications

Senthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.


Emily Z. Touloukian

Latest:

Can Just-in-Time Clinical Trials Reduce Disparities in Participation?

Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.



Nancy Lin, MD

Latest:

Survival Advantage Observed in HER2+Breast Cancer With Brain Metastasis

Nancy U. Lin, MD, discusses the results from a substudy of HER2CLIMB looking at tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer and brain metastases.


Benjamin Besse, MD, PhD

Latest:

Biomarker Analysis Predicts Post-Osimertinib Response in EGFR+ NSCLC

Benjamin Besse, MD, PhD, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.


Ashling Wahner

Latest:

Survival Benefits Shown After Stem Cell Transplant With Orca-T Vs PTCy

Orca-T demonstrated survival rates vs post-transplant cyclophosphamide in patients with hematologic malignancies receiving myeloablative conditioning, according to findings from a retrospective analysis.


Heinz Ludwig, MD

Latest:

Increased Rates of Viral Infections in Multiple Myeloma

Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.


Christine Dierks, MD

Latest:

Outcomes Underscore Need for New Agents to Treat Anaplastic Thyroid Carcinoma

Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.


Nicolaus Kröger, MD

Latest:

Comparing Tandem Stem Cell Transplant Approaches in Multiple Myeloma

Nicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.


Yao Yu, MD

Latest:

JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCC

The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.


Bruno Sangro, MD, PhD

Latest:

Improving Upon Immunotherapy Advances in HCC

Bruno Sangro, MD, PhD, discusses the key takeaways from recent data in the treatment landscape of patients with hepatocellular carcinoma.


Thomas Habermann, MD

Latest:

Unmet Needs Remain Unfilled in the Diffuse Large B-Cell Lymphoma Space

Thomas Habermann, MD, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma.


Charles Meakin, MD, MHA

Latest:

Colorectal Cancer Awareness Month: Overcoming Barriers to Early Detection

Charles Meakin, MD, MHA, chief medical officer of Care Oncology, discusses the current colorectal cancer landscape, innovations in detection, and improving patient screening and follow-up care for Colorectal Cancer Awareness Month.


Rebecca A. Shatsky, MD

Latest:

Advantages of SC HER2 Therapy Over IV Administration in Breast Cancer

Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.


Toufic Kachaamy, MD

Latest:

Artificial Intelligence and Machine Learning in Cancer Detection

Artificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.


Efstathios Kastritis, MD

Latest:

Daratumumab Regimen May Be the More Active Therapy Needed for Amyloidosis

Efstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.


Sponsored Content by The Janssen Pharmaceutical Companies of Johnson & Johnson

Latest:

Precise Management of EGFR exon 20-Positive Non–Small Cell Lung Cancer

Research shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.


Hannah Burke

Latest:

Company-wide Initiative Will Provide Standards for Collection and Storage

The Florida Cancer Specialists & Research Institute's Data Governance Committee was established to oversee the program’s implementation and monitor its progress.


Michael Tees, MD

Latest:

The Promise of ALLO-501A in Relapsed/Refractory LBCL

Michael T. Tees, MD, discusses the data behind ALLO-501A, an allogeneic chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma.



Prerna Mewawalla, MD

Latest:

An Explosion of Agents for Myeloma Treatment

Prerna Mewawalla, MD, discusses how the treatment landscape for multiple myeloma is growing.


Chad A. Hamilton, MD

Latest:

Future Perspectives and Unmet Needs in the Treatment of Ovarian Cancer

Chad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.


William H. Bradley, MD

Latest:

Olaparib Trial Supports 2-Year Treatment Duration in Ovarian Cancer

William H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.


Matthew J. Frigault, MD, MS

Latest:

CAR T Benefits in Cancer Outweigh Potential Risk of Secondary Malignancies

Matthew J. Frigault, MD, MS, discussed what a community oncologist should know about the ongoing FDA investigation of chimeric antigen receptor T-cell therapies.